Skip to main
LUNG

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 0%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Pulmonx is a category leader in the bronchoscopic lung volume reduction market with a strong product portfolio, including Zephyr valves and the Chartis assessment system. While the company has faced challenges in the past, recent restructuring efforts have improved operating efficiency and narrowed losses, culminating in a solid full-year earnings report. With an upcoming earnings cycle focused on U.S. procedure growth and improved sales metrics, Pulmonx has the potential for strong revenue growth and improved profitability in the future.

Bears say

Pulmonx is facing significant risk factors and uncertainties, including clinical and regulatory challenges, financial risks, and market share challenges. While the company reported modest annual growth in its recent financial results, it also highlighted weaker quarterly performance and a transitional period. The company's future revenue growth and profitability also depend on its ability to overcome collateral ventilation limitations and successfully execute its strategy to expand its addressable market. Without solid evidence of improved sales execution, it is difficult to have a positive outlook on the company's stock.

Pulmonx (LUNG) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 0% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 7 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.